Total Payments
$41,709
2024 Payments
$37,537
Companies
4
Transactions
18
Medicare Patients
1,966
Medicare Billing
$127,614
Payment Breakdown by Category
Other$28,710 (68.8%)
Consulting$7,667 (18.4%)
Travel$4,967 (11.9%)
Food & Beverage$365.17 (0.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $28,710 | 7 | 68.8% |
| Consulting Fee | $7,667 | 3 | 18.4% |
| Travel and Lodging | $4,967 | 6 | 11.9% |
| Food and Beverage | $365.17 | 2 | 0.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $34,042 | 15 | $0 (2024) |
| Alnylam Pharmaceuticals Inc. | $3,150 | 1 | $0 (2021) |
| AstraZeneca Pharmaceuticals LP | $2,417 | 1 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $2,100 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $37,537 | 14 | PFIZER INC. ($33,021) |
| 2023 | $1,003 | 2 | PFIZER INC. ($1,003) |
| 2021 | $3,150 | 1 | Alnylam Pharmaceuticals Inc. ($3,150) |
| 2019 | $18.53 | 1 | PFIZER INC. ($18.53) |
All Payment Transactions
18 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | PFIZER INC. | VYNDAMAX (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $600.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/26/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $2,416.50 | General |
| 11/12/2024 | PFIZER INC. | VYNDAMAX (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,800.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/22/2024 | PFIZER INTERNATIONAL LLC | VYNDAQEL (Drug) | Travel and Lodging | In-kind items and services | $221.24 | General |
| Category: CARDIOVASCULAR | ||||||
| 09/12/2024 | PFIZER INTERNATIONAL LLC | VYNDAQEL (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $10,860.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 09/10/2024 | PFIZER INC. | VYNDAQEL (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,600.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 08/28/2024 | PFIZER INC. | VYNDAQEL (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $300.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 08/16/2024 | PFIZER INC. | VYNDAMAX (Drug) | Travel and Lodging | In-kind items and services | $1,804.01 | General |
| Category: CARDIOVASCULAR | ||||||
| 08/09/2024 | Alexion Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,100.00 | General |
| 08/01/2024 | PFIZER INC. | VYNDAQEL (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,300.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 06/28/2024 | PFIZER INC. | VYNDAQEL (Drug) | Travel and Lodging | Cash or cash equivalent | $249.98 | General |
| Category: CARDIOVASCULAR | ||||||
| 05/26/2024 | PFIZER INC. | VYNDAQEL (Drug) | Travel and Lodging | In-kind items and services | $1,466.46 | General |
| Category: CARDIOVASCULAR | ||||||
| 05/26/2024 | PFIZER INC. | VYNDAQEL (Drug) | Travel and Lodging | In-kind items and services | $569.12 | General |
| Category: CARDIOVASCULAR | ||||||
| 01/12/2024 | PFIZER INC. | VYNDAQEL (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,250.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/02/2023 | PFIZER INC. | VYNDAQEL (Drug) | Travel and Lodging | In-kind items and services | $656.43 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/02/2023 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $346.64 | General |
| Category: CARDIOVASCULAR | ||||||
| 01/08/2021 | Alnylam Pharmaceuticals Inc. | ONPATTRO (Drug) | Consulting Fee | Cash or cash equivalent | $3,150.00 | General |
| Category: Genetic Disease | ||||||
| 05/13/2019 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $18.53 | General |
| Category: CARDIOVASCULAR | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 622 | 664 | $211,230 | $40,403 |
| 2022 | 13 | 500 | 574 | $182,845 | $37,779 |
| 2021 | 12 | 636 | 679 | $209,545 | $37,214 |
| 2020 | 6 | 208 | 236 | $65,395 | $12,219 |
Total Patients
1,966
Total Services
2,153
Medicare Billing
$127,614
Procedure Codes
49
All Medicare Procedures & Services
49 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 56 | 75 | $37,125 | $10,404 | 28.0% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 123 | 123 | $48,695 | $7,949 | 16.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 56 | 67 | $25,125 | $6,656 | 26.5% |
| 78431 | Nuclear medicine studies of blood flow in heart muscle at rest and with stress with concurrent ct scan | Facility | 2023 | 45 | 45 | $16,875 | $3,223 | 19.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 19 | 24 | $11,880 | $2,906 | 24.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 39 | 43 | $10,965 | $2,496 | 22.8% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Facility | 2023 | 36 | 36 | $13,680 | $2,108 | 15.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 11 | 11 | $7,535 | $1,342 | 17.8% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 91 | 94 | $15,040 | $1,094 | 7.3% |
| 78434 | Nuclear medicine study of heart muscle blood flow by pet | Facility | 2023 | 45 | 45 | $5,625 | $1,079 | 19.2% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Office | 2023 | 52 | 52 | $9,620 | $607.88 | 6.3% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Facility | 2023 | 49 | 49 | $9,065 | $537.74 | 5.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 38 | 51 | $25,245 | $7,434 | 29.4% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2022 | 80 | 80 | $38,875 | $6,331 | 16.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 47 | 53 | $19,875 | $5,533 | 27.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 22 | 54 | $13,500 | $3,268 | 24.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 42 | 44 | $11,220 | $2,908 | 25.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 13 | 21 | $10,395 | $2,590 | 24.9% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 13 | 20 | $7,100 | $1,786 | 25.2% |
| 78431 | Nuclear medicine studies of blood flow in heart muscle at rest and with stress with concurrent ct scan | Facility | 2022 | 20 | 20 | $7,500 | $1,508 | 20.1% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 11 | 12 | $5,640 | $1,283 | 22.7% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 15 | 15 | $5,625 | $1,114 | 19.8% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 91 | 95 | $15,200 | $1,104 | 7.3% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Facility | 2022 | 15 | 15 | $5,700 | $967.14 | 17.0% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 11 | 12 | $3,000 | $720.28 | 24.0% |
About Dr. Cesia Maria Gallegos Kattan, MD
Dr. Cesia Maria Gallegos Kattan, MD is a Cardiovascular Disease healthcare provider based in New Haven, Connecticut. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/12/2012. The National Provider Identifier (NPI) number assigned to this provider is 1376805622.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Cesia Maria Gallegos Kattan, MD has received a total of $41,709 in payments from pharmaceutical and medical device companies, with $37,537 received in 2024. These payments were reported across 18 transactions from 4 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($28,710).
As a Medicare-enrolled provider, Gallegos Kattan has provided services to 1,966 Medicare beneficiaries, totaling 2,153 services with total Medicare billing of $127,614. Data is available for 4 years (2020–2023), covering 49 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Other Specialties Student in an Organized Health Care Education/Training Program
- Location New Haven, CT
- Active Since 06/12/2012
- Last Updated 05/12/2020
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1376805622
Products in Payments
- VYNDAQEL (Drug) $26,838
- VYNDAMAX (Drug) $7,204
- ONPATTRO (Drug) $3,150
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in New Haven
Dr. Jeffrey Testani, M.d, M.D
Cardiovascular Disease — Payments: $625,767
Cardiovascular Disease $625,767
Henry Ward, M.d, M.D
Cardiovascular Disease — Payments: $404,260
Cardiovascular Disease $404,260
Dr. John Forrest, M.d, M.D
Cardiovascular Disease — Payments: $232,147
Cardiovascular Disease $232,147
Dr. Alexandra Lansky, Md, MD
Cardiovascular Disease — Payments: $205,439
Cardiovascular Disease $205,439
Dr. Hyung Chun, Md, MD
Cardiovascular Disease — Payments: $180,221
Cardiovascular Disease $180,221
Lissa Sugeng, Md, Mph, MD, MPH
Cardiovascular Disease — Payments: $106,815
Cardiovascular Disease $106,815